Yeah, as I said, so for a final conclusion, it is certainly better to have randomized data. One reason why we conducted AXSANA as a prospective study or prospective cohort registry study was that it’s very difficult for surgical trials to get the funding for these trials. So this is very difficult. That’s why we started AXSANA as a prospective registry. However, within this registry where we have an established network with more than 300 sites, we have ethical approval...
Yeah, as I said, so for a final conclusion, it is certainly better to have randomized data. One reason why we conducted AXSANA as a prospective study or prospective cohort registry study was that it’s very difficult for surgical trials to get the funding for these trials. So this is very difficult. That’s why we started AXSANA as a prospective registry. However, within this registry where we have an established network with more than 300 sites, we have ethical approval. All techniques that are applied in the study are not experimental. So we can, within this cohort study, we can perform a randomization without additional costs. And this is a very elegant way to include a randomisation which is an in-registry randomization and then give answers and solve the remaining issues to compare sentinel-lymph node biopsy and TAD.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.